-
Type:
Change Request
-
Resolution: Retracted
-
Priority:
Medium
-
Genomics Reporting (FHIR)
-
STU3
-
Clinical Genomics
-
documentation [deprecated]
-
1.5.2
-
-
Enhancement
In the Genetic Impact profile, the level of evidence is 0..1 and perhaps should be 0..*? For example, in the case of PGx, CPIC and PharmGKB (and maybe others) might have different levels.
Reviewing the gene-drugs on CPIC (https://cpicpgx.org/genes-drugs/), I can imagine someone wanting to send CPIC Level, PharmGKB Level of Evidence, and even PGX on FDA Label to help the receiving system better drive the appropriate usage of the impact.
NOTE - Perhaps "PGX on FDA Label" is not a level of evidence but is instead its own component? Or maybe something else?
NOTE2 - This certainly falls into the category of "pre-coordinating CDS", and as such should perhaps fall into another "knowledge resource".
Please see the following page for more background: https://cpicpgx.org/prioritization/
- is voted on by
-
BALLOT-5402 Affirmative - Kevin Power : 2018-May-FHIR IG CG R1
- Retracted